Press Releases

Sanobiotec Minor Cannabinoids Making Way to US Market as It Closes Deal with Open Book Extracts

Written by Shared Content

The new partnership will present new scaling opportunities for novel cannabinoids, including CBN, CBC, THCV, and CBDV 

November 11, 2020. Sanobiotec, a cannabinoid science company, leading in research, discovery and development of novel cannabinoids, today announced a new partnership with Open Book Extracts (OBX), manufacturer and distributor of the industry’s most innovative and highest quality cannabinoid ingredients and finished products. Along with more prospects for research and accelerated distribution, the partnership will drive further commercialization of Sanobiotec’s products, strengthening its position as an industry-accredited supplier of high-purity minor cannabinoids.

The partnership between Sanobiotec and OBX is a major step towards accelerating the commercialization and distribution of pure and stable cannabinoids at scale.

“We pride ourselves on identifying promising and innovative companies such as Sanobiotec and partnering with them to grow and accelerate their distribution. We are pleased to enter into this exclusive distribution partnership with Sanobiotec and look forward to increasing awareness and availability of their premium rare cannabinoids throughout the pharmaceutical, wellness, and cosmetics industries,” explains Dave Neundorfer, CEO at OBX.

OBX has a wide distribution network, including established CBD brands, CPGs, multi-state operators, manufacturers, and research laboratories. Having Sanobiotec on board will enable OBX to supply the US market with a full portfolio of minor cannabinoids that are currently in great demand. As a result of relentless innovation in both R&D and production processes, Sanobiotec is able to offer these novel highest quality cannabinoids at competitive pricing while at the same time ensuring high volume production and availability.

Rytis V. Urbonas, CEO at Sanobiotec, notes that being recognized as an industry-leading manufacturer of minor cannabinoids reflects Sanobiotec’s consistent and innovative work in the industry towards becoming a global hub for cannabinoid research and development, leading to the creation of proprietary production solutions, as well as refining a top-tier product suite.

“OBX is the category leader in non-THC cannabinoids, with a reputation for providing their clients with innovative, high-quality ingredients and unparalleled service,” said Rytis V. Urbonas. “Through our exclusive partnership with OBX and their well-established distribution network, we are pleased to accelerate the distribution of Sanobiotec’s rare cannabinoid ingredients in the US market.”

He also added that expanding the supply of high-purity products will act as a stimulus for market players to explore compound applicability with greater consistency.

“This will further advance the understanding of cannabinoids in general,“ continued Urbonas,” as expanding supply affirms the need for researchers’ work and creates an incentive for them to delve even deeper.”

With an expert team of researchers and scientists, Sanobiotec aims to continue identifying most promising compounds and developing novel methods to produce them at purity and scale. Recently, Sanobiotec announced the synthesis of pure and stable Tetrahydrocannabivarin (THCV), as well as refined methods to produce CBN, CBC, and CBDV at commercial scale. Amongst the company’s future milestones are synthesizing CBGM (Cannabigerol Monomethyl Ether), CBL (Cannabicyclol), CBT (Cannabitriol), and Cannflavin A.



Sanobiotec is a cannabinoid science company committed to identification, development, and formulation of innovative active compounds via natural hemp extraction, synthesis, and biosynthesis. Headquartered in Vilnius, Lithuania, the company operates a state-of-the-art laboratory and develops proprietary technological solutions designed for the production of natural and custom compounds. Sanobiotec is also engaged in scientific research projects investigating the potential of cannabinoid-based medications used for treatment of specific diseases.

For more information visit: and


Headquartered in Roxboro, N.C., Open Book Extracts is a cGMP-certified manufacturer of premium plant-based cannabinoid products, aiming to be the industry’s true north by delivering premium products, exceptional service, and industry-leading transparency. With control of the entire supply chain, a state-of-the-art extraction campus near North Carolina’s Research Triangle, proprietary refinement and conversion methods backed by a growing IP portfolio, and a team of PhD chemists and seasoned business leaders, OBX is the trusted partner for global brands seeking to enter the marketplace. OBX Asia, with its headquarters in Hong Kong, provides strategic guidance and on-the-ground support for our Asia customers.

For more information, visit

Media contact:

Ieva Mackeviciute

[email protected]

About the author

Shared Content